News
NAMS
23.81
+0.98%
0.23
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)
TipRanks · 5h ago
NewAmsterdam Pharma Begins Phase 2b Preclinical Alzheimer’s Trial
TipRanks · 9h ago
NewAmsterdam Pharma doses first participant in Phase 2b SPINOZA trial
TipRanks · 10h ago
NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease
Benzinga · 10h ago
Weekly Report: what happened at NAMS last week (0921-0925)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 09/22 12:20
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), NewAmsterdam Pharma Company (NAMS)
TipRanks · 09/22 12:10
EU Approval of Obicetrapib Products Strengthens NewAmsterdam
TipRanks · 09/21 21:22
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
TipRanks · 09/21 16:10
NewAmsterdam Wins First Global Approval For Obicetrapib Cholesteorl Treatments
NASDAQ · 09/21 14:44
NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia
Benzinga · 09/21 13:03
Weekly Report: what happened at NAMS last week (0914-0918)?
Weekly Report · 09/21 10:07
Analyst Reiterates Buy on NewAmsterdam Pharma as PREVAIL Study Changes and Interim Analysis Boost Confidence in Obicetrapib’s Cardiovascular Outcomes
TipRanks · 09/18 08:45
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
NASDAQ · 09/15 12:47
Weekly Report: what happened at NAMS last week (0907-0911)?
Weekly Report · 09/14 10:11
NewAmsterdam Pharma: Potential Coupled With Uncertainty
Seeking Alpha · 09/08 14:08
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 09/08 12:01
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 09/08 11:40
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Merck & Company (MRK) and Royalty Pharma (RPRX)
TipRanks · 09/08 11:30
NewAmsterdam Pharma Price Target Maintained With a $52.00/Share by HC Wainwright & Co.
Dow Jones · 09/08 11:00
More
Webull provides a variety of real-time NAMS stock news. You can receive the latest news about NewAmsterdam Pharma Company N.V through multiple platforms. This information may help you make smarter investment decisions.
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.